Business
CytoSorbents Enters Agreement with China Medical System Holdings Limited to Bring CytoSorb to Mainland China to Treat Critically-ill Patients with COVID-19 Coronavirus Infection
MONMOUTH JUNCTION, N.J. and NORTH POINT, Hong Kong, Feb. 19, 2020 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy
About this update from Cytosorbents Corporation
[{"type":"text","content":"MONMOUTH JUNCTION, N.J. and NORTH POINT, Hong Kong, Feb. 19, 2020 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader with more than 80,000 global treatments of its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients, and China Medical System Holdings Limited (CMS) (HKG:0867), a well-established, innovation-driven specialty pharma with a focus on sales and marketing in China and Asia, entered into an agreement to bring CytoSorb to mainland China to treat critically-ill patients with COVID-19 (fka Wuhan or 2019-nCoV) coronavirus infection.\n\n \n \n\n \nUnder the terms of the agreement, CytoSorbents and CMS will partner together to earn regulatory clearance to import CytoSorb into China under the \"fast-track\" review process established by the National Medical Products Administration of the People's Republic of China (NMPA) to respond to the 2019 novel coronavirus (COVID-19) pandemic. CytoSorbents will donate initial CytoSorb devices and provide product, training, and support to CMS to introduce CytoSorb initially into four hospitals in the Wuhan, China area. The therapy will be evaluated in severe COVID-19 coronavirus patients with a systemic inflammatory response who are being treated with either continuous renal replacement therapy (CRRT) or extracorporeal membrane oxygenation (ECMO). During the initial term of the agreement, CytoSorbents and CMS will explore the possibility for future commercial collaboration in China. The financial terms of the agreement have not been disclosed.\nMr. Chris Cramer, Vice President of Business Development of CytoSorbents, commented, \"We are excited to collaborate with CMS to bring CytoSorb to the patients and physicians in China that are dealing with this devastating COVID-19 coronavirus pandemic. To date, this infection has killed approximately 2-3 out of every 100 patients it infects, mainly by causing severe lung injury and acute respiratory distress syndrome (ARDS), shock, and multi-organ failure. Though CytoSorb has not yet been used to specifically treat patients infected with the COVID-19 coronavirus, it has been used to help treat shock, ARDS, multi-organ failure, and other complications of cytokine storm and excessive, deadly inflammation in thousands of patients with both bacter...